

Intratech Medical Shareholders Update – Q1 2022

Dear Shareholders,

I am happy to update you on our progress as we near the end of the second quarter of 2022.

Following the last update from Q1 2022, we are pleased to update you that we have enrolled two patients in our FIH study. Both patients were enrolled at the [Helsicore](#) medical center in Tbilisi.

The procedures were very successful in all aspects; Dr. Irakli, Head of the Interventional Cardiology Department at Helsicore, performed the cases and stated that the usability of the Booster balloon was easy (preparation, delivery, inflation, and deflation), there were no safety issues, and both patients are perfectly fine a few weeks after the procedures.

Dr. Irakli: “We are very proud to be the first-ever center in the world to use the Booster balloon for the treatment of patients after acute myocardial infarction. No learning curve is needed. It’s a very user-friendly device and we are confident to perform more cases.”

Enrolling two patients in the FIH study is a huge milestone for Intratech due to the inherent challenge of enrolling patients undergoing the most severe type of heart attack. I would like to acknowledge our CEO, Tsachi Doner, who has traveled to Georgia four times in the past two months (for a week each time) to support the local doctors in their first cases. Tsachi is planning to travel to Georgia several times again in the upcoming months.

We are happy to share that we have also received approval to launch the study in HaEmek MC in Israel, which will boost our enrollment efforts.

I want to thank all of you for your continued support in our efforts and for enabling us to reach these important milestones. Please feel free to contact me directly with any questions you may have.

I wish you an enjoyable summer and stay safe!

Sincerely yours,

Moshe Barel, Chairman

Intratech Medical



moshe@intratechmedical.com